Breaking News Instant updates and real-time market news.

RHHBY

Roche

$0.00

(0.00%)

13:39
10/21/18
10/21
13:39
10/21/18
13:39

Entrectinib shrank tumors in people with NTRK fusion-positive solid tumors

Genentech, a member of the Roche, announced results from an integrated analysis of the pivotal Phase II STARTRK-2, Phase I STARTRK-1 and Phase I ALKA-372-001 trials that showed the investigational personalized medicine entrectinib shrank tumors in more than half of people with neurotrophic tropomyosin receptor kinase fusion-positive solid tumors. Objective responses to entrectinib were seen across 10 different solid tumor types, including in people with and without central nervous system metastases at baseline. Importantly, entrectinib shrank tumors that had spread to the brain in over half of people, with more than a quarter of these people having a complete response. The safety profile of entrectinib was consistent with that seen in previous analyses. Entrectinib has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for the treatment of NTRK fusion-positive, locally advanced or metastatic solid tumors in adult and pediatric patients who have either progressed following prior therapies or have no acceptable standard therapies. Breakthrough Therapy Designation is designed to expedite the development and review of medicines intended to treat serious or life-threatening diseases and to help ensure people have access to them through FDA approval as soon as possible. Genentech plans to submit results from these integrated analyses to global health authorities for the treatment of NTRK fusion-positive solid tumors and ROS1-positive NSCLC.

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

RHHBY Roche
$0.00

(0.00%)

10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/15/18
RBCM
10/15/18
NO CHANGE
RBCM
Sector Perform
Roche breast cancer data could pressure Puma shares, says RBC Capital
RBC Capital analyst Kennen MacKay thinks the data presented this morning by Roche's (RHHBY) Genentech could pressure shares of Puma Biotechnology (PBYI) today. Genentech announced the Phase III Katherine study met its primary endpoint, showing Kadcyla as a single agent reduced the risk of disease recurrence or death compared to Herceptin as an adjuvant treatment in people with HER2-positive early breast cancer who have residual disease present following neoadjuvant treatment. Kadcyla's ultimate entry into the HER2-positive adjuvant setting could complicate the positioning of Puma's Nerlynx, MacKay tells investors in a research note. He keeps a Sector Perform rating on shares of Puma, which are down 4%, or $1.55, to $41.14 in morning trading.
10/08/18
SBSH
10/08/18
NO CHANGE
Target $470
SBSH
Buy
Biogen price target lowered to $470 from $483 at Citi
Citi analyst Robyn Karnauskas lowered her price target for Biogen (BIIB) to $470 after reducing her assumptions for Rituxan/Gazyva co-promotion profits to reflect greater erosion from biosimilar versions of Rituxan that are expected to launch late 2018/early 2019. The analyst points out that consensus estimates are not modeling significant co-promotion profit erosion from Rituxan biosimilars. However, the Roche (RHHBY) consensus for Rituxan has steep declines in Rituxan sales, Karnauskas tells investors in a research note. The analyst now models a 45% total decline in Rituxan/Gazyva U.S. sales over 2018-2023. She keeps a Buy rating on Biogen.
10/03/18
BARD
10/03/18
NO CHANGE
Target $348
BARD
Neutral
Risdiplam data incrementally negative for Biogen, says Baird
Biogen analyst Brian Skorney views this morning's risdiplam data for use in treating spinal muscular atrophy patients as incrementally negative for Biogen (BIIB). The data from PTC Therapeutics (PTCT) and PTC Therapeutics (RHHBY) are compelling so far, and suggest that risdiplam could impact the market share of Biogen's Spinraza, if it comes to market, Skorney tells investors in a research note. He highlights risdiplam's convenience as an oral small molecule and says the Phase II data "continues to impress." The analyst keeps a Neutral rating on Biogen with a $348 price target. The stock in afternoon trading is up $6.90, or 2%, to $352.31.

TODAY'S FREE FLY STORIES

02:35
11/21/18
11/21
02:35
11/21/18
02:35
General news
FX Update: The Dollar majors have traded mixed »

FX Update: The Dollar…

02:00
11/21/18
11/21
02:00
11/21/18
02:00
General news
FX Action: USD-JPY has traded moderately firmer »

FX Action: USD-JPY has…

01:45
11/21/18
11/21
01:45
11/21/18
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

MDT

Medtronic

$92.31

1.91 (2.11%)

20:48
11/20/18
11/20
20:48
11/20/18
20:48
Recommendations
Medtronic analyst commentary at Piper Jaffray »

Medtronic in the midst of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

RDY

Dr. Reddy's

$36.48

1.19 (3.37%)

20:44
11/20/18
11/20
20:44
11/20/18
20:44
Hot Stocks
Dr. Reddy's announces favorable outcome in Buprenorphine and Naloxone litigation »

Dr. Reddy's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCCO

Southern Copper

$35.63

-1.615 (-4.34%)

20:30
11/20/18
11/20
20:30
11/20/18
20:30
Upgrade
Southern Copper rating change at Bradesco »

Southern Copper upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBH

KB Home

$19.84

0.37 (1.90%)

20:17
11/20/18
11/20
20:17
11/20/18
20:17
Hot Stocks
KB Home expands into Seattle housing market »

KB Home announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLDR

Cloudera

$10.69

-0.545 (-4.85%)

20:16
11/20/18
11/20
20:16
11/20/18
20:16
Hot Stocks
Cloudera partners with Bank Rakyat Indonesia »

Cloudera announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

AAPL

Apple

$177.10

-8.7 (-4.68%)

19:44
11/20/18
11/20
19:44
11/20/18
19:44
Periodicals
Apple acquires AI software firm Silk Labs, The Information reports »

Apple is said to have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

NVT

nVent Electric

$24.18

-0.35 (-1.43%)

19:20
11/20/18
11/20
19:20
11/20/18
19:20
Initiation
nVent Electric initiated at Vertical Research »

nVent Electric initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

FB

Facebook

$132.47

0.85 (0.65%)

19:13
11/20/18
11/20
19:13
11/20/18
19:13
Periodicals
Russia's FAN sues Facebook, claims to be legitimate news outlet, Reuters says »

Facebook is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

CMCSA

Comcast

$36.75

-1.44 (-3.77%)

, CMCSK

Comcast

$0.00

(0.00%)

18:58
11/20/18
11/20
18:58
11/20/18
18:58
Periodicals
Megyn Kelly seen to leave NBC News with entirety of $69M deal, WSJ says »

Megyn Kelly is…

CMCSA

Comcast

$36.75

-1.44 (-3.77%)

CMCSK

Comcast

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

FL

Foot Locker

$46.10

-2.69 (-5.51%)

, ADSK

Autodesk

$122.99

-2.76 (-2.19%)

18:56
11/20/18
11/20
18:56
11/20/18
18:56
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Foot…

FL

Foot Locker

$46.10

-2.69 (-5.51%)

ADSK

Autodesk

$122.99

-2.76 (-2.19%)

BJ

BJ's Wholesale

$19.85

-0.22 (-1.10%)

KEYS

Keysight Technologies

$54.35

-1.23 (-2.21%)

CPRT

Copart

$47.30

-1.255 (-2.58%)

VNET

21Vianet

$11.20

-0.1 (-0.88%)

GPS

Gap

$24.65

-0.79 (-3.11%)

BILI

Bilibili

$13.61

0.575 (4.41%)

DXCM

DexCom

$119.89

-1.34 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 26

    Nov

  • 27

    Nov

  • 04

    Dec

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 03

    Mar

AAPL

Apple

$177.10

-8.7 (-4.68%)

18:46
11/20/18
11/20
18:46
11/20/18
18:46
Periodicals
Apple in discussions to give vets access to electronic medical records, WSJ says »

Apple is in talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

FB

Facebook

$132.47

0.85 (0.65%)

18:32
11/20/18
11/20
18:32
11/20/18
18:32
Periodicals
Facebook ads system was down today for some users, Bloomberg says »

Facebook's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

EMCI

EMC Insurance

$32.33

1.1 (3.52%)

18:28
11/20/18
11/20
18:28
11/20/18
18:28
Hot Stocks
EMC Insurance announces receipt of proposal from EMCC to buy all of its shares »

EMC Insurance announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEX

Emerald Expositions Events

$11.09

0.17 (1.56%)

18:26
11/20/18
11/20
18:26
11/20/18
18:26
Hot Stocks
Emerald Expositions Events announces $20M share repurchase program »

The company anticipates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIVN

LivaNova

$98.00

-22.28 (-18.52%)

18:26
11/20/18
11/20
18:26
11/20/18
18:26
Recommendations
LivaNova analyst commentary at Piper Jaffray »

LivaNova price decline on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 27

    Nov

BKH

Black Hills

$64.40

0.92 (1.45%)

18:24
11/20/18
11/20
18:24
11/20/18
18:24
Hot Stocks
Black Hills Energy receives approval to construct $54M gas pipeline in Wyoming »

Black Hills announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,026.00

7 (0.69%)

, GOOGL

Alphabet Class A

$1,031.22

4.99 (0.49%)

18:19
11/20/18
11/20
18:19
11/20/18
18:19
Periodicals
Google expands Moffett Park presence again, SVBJ says »

Google is once again…

GOOG

Alphabet

$1,026.00

7 (0.69%)

GOOGL

Alphabet Class A

$1,031.22

4.99 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 03

    Mar

SE

Sea Limited

$12.18

-0.52 (-4.09%)

18:04
11/20/18
11/20
18:04
11/20/18
18:04
Earnings
Sea Limited reports Q3 net loss ($237.6M) vs. ($127.1M) last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BILI

Bilibili

$13.61

0.575 (4.41%)

18:03
11/20/18
11/20
18:03
11/20/18
18:03
Earnings
Bilibili reports Q3 revenue $157.1M, consensus $146.72M »

Reports Q3 adjusted net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

LTM

Latam Airlines

$9.24

-0.4 (-4.15%)

18:01
11/20/18
11/20
18:01
11/20/18
18:01
Hot Stocks
Breaking Hot Stocks news story on Latam Airlines »

LATAM Airlines reports Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CE

Celanese

$100.26

-1.53 (-1.50%)

18:01
11/20/18
11/20
18:01
11/20/18
18:01
Hot Stocks
Celanese increases Fortron polyphenylene sulphide price by 85c per kg »

The price increases will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$317.77

-3.09 (-0.96%)

, TSLA

Tesla

$347.60

-5.88 (-1.66%)

17:55
11/20/18
11/20
17:55
11/20/18
17:55
Periodicals
NASA to investigate workplace culture at Boeing, SpaceX, Reuters says »

NASA said that it plans…

BA

Boeing

$317.77

-3.09 (-0.96%)

TSLA

Tesla

$347.60

-5.88 (-1.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 13

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.